{{Rsnum
|rsid=714368
|Gene=SLC22A16
|Chromosome=6
|position=110456925
|Orientation=minus
|GMAF=0.3058
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC22A16
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 61.6 | 35.7 | 2.7
| HCB | 29.1 | 50.0 | 20.9
| JPT | 39.4 | 51.4 | 9.2
| YRI | 34.5 | 53.1 | 12.4
| ASW | 41.1 | 50.0 | 8.9
| CHB | 29.1 | 50.0 | 20.9
| CHD | 32.1 | 47.7 | 20.2
| GIH | 58.6 | 37.4 | 4.0
| LWK | 45.7 | 43.8 | 10.5
| MEX | 57.1 | 35.7 | 7.1
| MKK | 40.6 | 42.6 | 16.8
| TSI | 51.5 | 40.4 | 8.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs714368
|Name_s=SLC22A16:146A>G; His49Arg
|Gene_s=SLC22A16
|Feature=
|Evidence=PubMed ID:17559346
|Annotation=Risk or phenotype-associated allele: G. Phenotype: The variant 146GG genotype was associated with increased exposure to doxorubicin and its active metabolite doxorubicinol. Study size: 62. Study population/ethnicity: Patients with Breast Neoplasms receiving adjuvant doxorubicin; Asian; Singapore. Type of association: PK.
|Drugs=doxorubicin
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165291870
}}

{{GET Evidence
|gene=SLC22A16
|aa_change=His49Arg
|aa_change_short=H49R
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs714368
|overall_frequency_n=2914
|overall_frequency_d=10758
|overall_frequency=0.270868
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=1
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}